Pfizer could have a new vaccine against the omicron variant in 100 days

In a period of 100 days, a vaccine could be developed against the new omicron variant of COVID-19, said the president and director of Pfizer Spain Sergio Rodríguez Márquez during his statements in the Congress of Deputies.

Before the Investigation Committee on the management of vaccines and the Vaccination Plan, Rodriguez noted that “We continue working with the different strains that have emerged. So far, the vaccine has been shown to remain effective. We are now testing the new omicron strain. It is analyzing whether there is a loss of effectiveness or not. Based on this, Pfizer’s commitment is to develop a new vaccine within 100 days “.

As the Infosalus media rescued, the president of Pfizer revealed that if the current vaccine not efficient against omicron, they would have a new one ready in a period of approximately 100 days.

“The technology on which the (mRNA) vaccine is based allows in a relatively short period to start developing and producing a vaccine that can be effective against this variant”, he indicated.

On the other hand, Rodriguez he claims to be proud of the role he has been developing Pfizer on Spain so far in the pandemic of COVID-19 indicating that “The distribution of the vaccine in the country has been excellent and fairly equitable. There have been no autonomous communities with greater or lesser access, it has been excellent despite the complexity that there was ”.

“It has worked, respecting the vaccination plans with each community, but ensuring equity for all Spaniards.”

However, he points out that work continues to ensure that the accessibility of the vaccine is not a problem worldwide. “There is a big logistics problem, but work continues to make it available worldwide depending on the production capacity we have”, he indicated.

Rodriguez wants to ensure dose distribution for low-resource countries so it shortened the manufacturing period from 110 to 90 days.

“Work has also been done to improve production in various ways. The production period has been shortened from 110 to 90 days. Agreements have been made with other companies to expand manufacturing. There is a commitment of 4,000 million doses by 2022, of which 2,000 will go to low-income countries ”, assured.

“We are working on agreements with different companies. More than technology transfer, what is important is that the vaccine is safe and effective. The quality has to be exactly the same for a citizen in Europe, Africa or whatever country it is “, ended.

RECOMMENDED VIDEO